Insights Into Acute Myeloid Leukemia – ASH Edition

Perspectives of community physicians from across the US on the management of newly diagnosed and relapsed/refractory (R/R) acute myeloid leukemia (AML)

December 16, 2020
Purchase Report

Faculty Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated, virtual roundtable discussion focusing on treatment of AML was held on December 16, 2020
  • Disease state and data presentations were developed in conjunction with Dr Elias Jabbour from MD Anderson Cancer Center
  • Insights on the following AML therapies were obtained: azacitidine, cytarabine and daunorubicin (ie, 7+3), decitabine, ivosidenib, enasidenib, gemtuzumab ozogamicin, gilteritinib, liposomal daunorubicin and cytarabine, midostaurin, sorafenib, venetoclax, and glasdegib

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 13 community oncologists from Arizona, Georgia, Massachusetts, New Jersey, New York, Florida, California, and South Carolina

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.